Craft

KYOWA HAKKO BIO

Revenue

¥53 B

FY, 2021

KYOWA HAKKO BIO Summary

Company Summary

Overview
KYOWA HAKKO BIO (協和発酵バイオ株式会社) is a company engaged in the development of biotechnology processes and products from fermentation and synthesis technologies. It supplies various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids.
Type
Subsidiary
Status
Active
Founded
2008
HQ
Chiyoda City, JP | view all locations
Website
http://www.kyowahakko-bio.co.jp/english/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Noriaki Kobayashi, Director of the Board

    • Toru Ishikura, Director of the Board

      • Chikao Urata, Managing Executive Officer

        • Yuki Kanzaki, Managing Executive Officer

          Operating MetricsView all

          Product Categories

          5

          May, 2022

          Plants (Domestic)

          1
          50.0%

          May, 2022

          Trademarks (US)

          15
          6.3%

          May, 2022

          LocationsView all

          12 locations detected

          • Chiyoda City, Tokyo HQ

            Japan

            Otemachi Finacial City Grand Cure, 1-chōme-9 Ōtemachi

          • New York, NY

            United States

            600 3rd Ave 19th Floor

          • Beijing, Beijing Shi

            China

            Room 2015, Beijing Fortune Bldg., No. 5 Dong San Huan Bei Lu, Chao Yang District

          • Guangzhou Shi, Guangdong Sheng

            China

            122 Liuhua Rd, Yuexiu Qu

          • Guangzhou Shi, Guangdong Sheng

            China

            RM.2208 22th Floor, Teem Tower,208 Tianhe Road, Tianhe District

          • Shanghai, Shanghai Shi

            China

            Room 1604 - 1605, Metro Plaza, No. 555, Lou Shan Guan Road, Changning District

          and 6 others

          KYOWA HAKKO BIO Financials

          Summary Financials

          Revenue (Y, 2021)
          $53.0B
          EBIT (Y, 2021)
          $400.0M

          Footer menu